Stacks
Longevity / 'Aging Clock' Stack Retatrutide + GHK-Cu + MOTS-c, SS-31 sequenced first — Fat loss + mitochondrial + inflammation — Jones DC.
⚠ Safety first — read this before anything else on this page Approval status: This stack is built on retatrutide — an investigational drug that has never been approved anywhere and legally exists only inside Eli Lilly's clinical trials. Anything sold as retatrutide outside those trials is, by definition, not the studied drug. The combination has never been tested. Full page: Retatrutide, in Dangers.
What has actually happened to people:
Products sold as retatrutide carry the worst current record in the gray market: two death reports in FDA's adverse-event system (unverified — a report is not a causal finding; CBS News, October 2026), 14 reported hospitalizations (Public Citizen, June 2026), and poison-center exposures tripling across 2026 — 249 calls in Q1, 460 in Q2, 862 in Q3 (America's Poison Centers via CBS). Eli Lilly states that suspect products it tested contained too much, too little, or the wrong active ingredient, plus contaminants. Eleven of fourteen sellers FDA warned were still advertising unapproved peptides months later (Public Citizen). GHK-Cu adds the copper-escalation risk (Dr. Froese's warning; see our copper page), and MOTS-c adds a compound for which FDA identified no human exposure data at all. What nobody knows: Retatrutide's safety outside Lilly's monitored trials is unknown; the stack's other layers are unstudied in humans; the four-way combination is beyond unstudied. Nothing in this stack has a human safety file a reader can consult.
Get medical care now if:
A racing heartbeat, severe vomiting or diarrhea, inability to keep fluids down, or severe abdominal pain — presentations in the retatrutide hospitalization record; seek care and name the product. Nausea, abdominal pain, unusual fatigue, or yellowing skin/eyes — possible copper-overload territory from the GHK-Cu layer; seek care. Swelling of the lips or tongue, or trouble breathing, after any injection — call emergency services. Who should stay away: Everyone, on the retatrutide layer alone — there is no lawful consumer version of this drug to be careful with. Specifically also: anyone with a cancer history (GHK-Cu/copper and angiogenesis questions), anyone managing blood sugar, minors, and anyone pregnant.
The product problem: Four injectables bought from a Brooklyn convenience store and lab-tested by WIRED (September 2026) — labeled BPC-157, PT-141, retatrutide, and NAD+ — contained no detectable match for any of their labeled ingredients.
Talk to a doctor who knows you are taking it. See our doctors directory . If you were harmed, report it to FDA MedWatch — your report is how the record gets built.
We don't publish doses, protocols, or sources — for any compound, ever. Our Legal Mandate .
Components: Retatrutide + GHK-Cu + MOTS-c, SS-31 sequenced first
What creators claim: Fat loss + mitochondrial + inflammation — Jones DC.
Evidence note: Retatrutide is investigational; stacking an investigational drug is this stack’s own headline risk.
Stub page — full treatment after the transcript bank is mined for this stack. No stack on this site carries instructions of any kind.
Educational information only — not medical or legal advice. Status as of November 7, 2026. See Our Legal Mandate .
Educational information only Not medical or legal advice. Always consult a licensed clinician.